Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.53 |
| ▸ | COMT | P21964 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14234863 | 0.76 | DRD2 (0.42) | DRD4ALDH1A1DRD2DRD3 | |
| SCHEMBL25054455 | 0.76 | CYP1A2 (0.43) | SIGMAR1POLBALDH1A1 | |
| SCHEMBL20691668 | 0.74 | LMNA (0.49) | SIGMAR1COMTMC4RDRD4POLB | |
| SCHEMBL31328891 | 0.74 | SIGMAR1 (0.49) | SIGMAR1COMTMC4RDRD4POLB | |
| SCHEMBL1991840 | 0.73 | SIGMAR1 (0.52) | SIGMAR1COMTMC4RDRD4POLB | |
| SCHEMBL17926166 | 0.73 | L3MBTL1 (0.43) | POLBALDH1A1DRD3KCNH2 | |
| SCHEMBL16682605 | 0.73 | SIGMAR1 (0.47) | SIGMAR1COMTMC4RDRD4POLB | |
| SCHEMBL2489199 | 0.72 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4POLBLMNA | |
| SCHEMBL1415730 | 0.72 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4POLBLMNA | |
| SCHEMBL8188324 | 0.72 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293381-A1 | Therapeutic Compounds | CELGENE QUANTICEL RES INC (US) | 2024-09-05 | — | — | US | disclosed |
| CN-114853730-B | Compounds used as HPK1 kinase inhibitor, preparation method and application thereof | 中国药科大学 | 2024-03-26 | — | — | CN | disclosed |
| US-11890275-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. | 2024-02-06 | — | — | US | disclosed |
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| CN-114853730-A | Compound used as HPK1 kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-08-05 | — | — | CN | disclosed |
| US-20210205284-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210205284-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-11020380-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11020380-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
| US-20200163946-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200163946-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-10617680-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-10617680-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| WO-2018237349-A1 | INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON (US) | 2018-12-27 | — | — | WO | disclosed |
| US-20180296543-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2018-10-18 | — | — | US | disclosed |
| EP-2648723-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | Vanderbilt University (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078817-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020380-B2 | Therapeutic compounds | EP300, BRD4, BRD3 | SIGMAR1 4469/4885COMT 4076/4885MC4R 3317/4885 |
| US-20240293381-A1 | Therapeutic Compounds | EP300, BRD4, BRD3 | SIGMAR1 4469/4885COMT 4076/4885MC4R 3317/4885 |
| US-20200163946-A1 | THERAPEUTIC COMPOUNDS | EP300, BRD4, BRD3 | SIGMAR1 4469/4885COMT 4076/4885MC4R 3317/4885 |
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | SIGMAR1 1912/4885COMT 868/4885MC4R 1707/4885 |
| US-20180296543-A1 | THERAPEUTIC COMPOUNDS | EP300, BRD4, BRD3 | SIGMAR1 4469/4885COMT 4076/4885MC4R 3317/4885 |
| US-20210205284-A1 | THERAPEUTIC COMPOUNDS | EP300, BRD4, BRD3 | SIGMAR1 4469/4885COMT 4076/4885MC4R 3317/4885 |
| US-10617680-B2 | Therapeutic compounds | EP300, BRD4, BRD3 | SIGMAR1 4469/4885COMT 4076/4885MC4R 3317/4885 |
| US-11890275-B2 | Therapeutic compounds | EP300, BRD4, BRD3 | SIGMAR1 4469/4885COMT 4076/4885MC4R 3317/4885 |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | AARS1, GARS1, MTR | SIGMAR1 2516/4885COMT 719/4885MC4R 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.